Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 95 Show results per page	View Search Criteria \| Help With Results


1.		Consolidation Hemi-Body Irradiation plus Chemotherapy with CMFP (CTX/MTX/5-FU/PRED) or CAF (CTX/ADR/5-FU) for Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				70 and under				NCI				EST-PE-179

Last Modified: 12/17/2007 First Published: 12/1/1993


2.		Phase III Randomized Study of Tamoxifen vs Placebo in Women with Node-Positive or High Risk Node-Negative Breast Cancer Who Have Completed Adjuvant Combination Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				pre-/perimenopausal								CAN-NCIC-MA12 NCI-V93-0323, NCT00002542, MA12

Last Modified: 6/1/1999


3.		Phase III Randomized Study of Mitoxantrone vs. Cyclophosphamide/Methotrexate/Fluorouracil (CMF) Chemotherapy for Good-Risk Metastatic Breast Cancer (Summary Last Modified 06/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				35 to 80								GER-AIO-02/92 EU-93010

Last Modified: 5/8/2007 First Published: 9/1/1994


4.		Phase III Randomized Study of Tamoxifen vs No Further Therapy Following Adjuvant Cyclophosphamide/Methotrexate/Fluorouracil (CMF) in Women with T1-3, N0-1, M0 Breast Cancer (Summary Last Modified 05/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				pre/postmenopausal								SCTN-BR9403 EU-94004, NCT00002579

Last Modified: 5/31/2007


5.		Phase III Randomized Study of Adjuvant Tamoxifen, Ovarian Suppression, and/or Chemotherapy in Women With Stage I, II, and IIIA Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified								NCRI-ABC CRC-TU-BR3010, SCTN-BR9401/BR9402, YRCO-ABC, EU-94029, UKCCCR-ABC, NCT00002582

Last Modified: 5/12/2008


6.		Phase III Randomized Study of Adjuvant Cyclophosphamide/Methotrexate/Fluorouracil (CMF) Followed by Tamoxifen vs Tamoxifen Alone in Postmenopausal Women with Operable, Node-Negative Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				over 16								IBCSG-IX EU-94040

Last Modified: 10/1/1998


7.		Phase III Randomized Study of Adjuvant Cyclophosphamide/Methotrexate/Fluorouracil (CMF) vs Total Estrogen Blockade for Pre-/Perimenopausal Women with ER-Positive, Stage II Breast Cancer with 1-9 Positive Nodes (Summary Last Modified 10/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				pre/perimenopausal 30 and over								CNR-GROCTA-010209 EU-93018

Last Modified: 1/1/1998


8.		Phase II Study of Multimodality Therapy for Women with Locally Advanced Breast Cancer: Neoadjuvant Cyclophosphamide/Doxorubicin/Fluorouracil (CAF) Followed by Radiotherapy with Mitomycin Followed by Surgery Followed by Adjuvant CAF or Mitoxantrone/Fluorouracil/Leucovorin (Summary Last Modified 01/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				20 to 65				Other				YALE-HIC-7996 NCI-V95-0728

Last Modified: 12/28/2006


9.		Phase III Randomized Study of Neoadjuvant Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) in Women With Stage III Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Temporarily closed				21 to 75				Other				GOCS-08-BR-95-III NCI-F95-0036, NCT00002696

Last Modified: 5/8/2007 First Published: 6/1/1996


10.		Phase III Randomized Study of Doxorubicin Induction Followed by Either Conventional Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) or High Dose Cyclophosphamide and Thiotepa with Peripheral Blood Stem Cell Rescue in Women With Stage II or IIIA Breast Cancer (Summary Last Modified 05/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				over 18								SCTN-BR9405 EU-95048, NCT00002755

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute